TG Therapeutics Inc TGTX is trading lower Monday after the company announced worse-than-expected second-quarter financial results and H.C. Wainwright lowered its price target.
TG Therapeutics reported a quarterly earnings loss of 59 cents per share, which came in below the estimate for a loss of 50 cents. The company reported quarterly revenue of $1.54 million, up from $38,000 year over year.
H.C. Wainwright & Co. analyst Edward White maintained TG Therapeutics with a Buy rating and lowered the price target from $89 to $84.
The analyst said that the company gained access to customers as a result of COVID-19, which he expects could be a challenge moving into 2022.
Price Action: TG Therapeutics has traded as high as $56.74 and as low as $17.67 over a 52-week period.
At last check Monday, the stock was down 21.80% at $27.36.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
